Immutep Reports Mixed Q2: Efti OS Benefit, TACTI-004 Futility
Immutep provided a quarterly update, highlighting a pooled analysis of five efti trials that demonstrated a 7.7-month median overall survival benefit in biological responders. The company also reported positive first-in-human Phase I results for IMP761, meeting its primary safety endpoint and showing significant pharmacodynamic activity. However, the Phase III TACTI-004 trial was discontinued due to a futility outcome, with a root cause analysis ongoing. Immutep remains well-funded with A$68.87 million in cash and expects its cash runway to extend into H1 CY28 due to cost-reduction measures.
Key Highlights
- Pooled analysis of efti trials showed 7.7-month median overall survival benefit.
- IMP761 Phase I met safety endpoint, showed significant pharmacodynamic activity.
- TACTI-004 Phase III trial discontinued due to futility analysis; root cause ongoing.
- A$68.87 million in cash, cash equivalents, and term deposits as of June 30, 2026.
- Cash runway extended into H1 CY28 due to cost-reduction measures.
- Received A$218K (EUR 133K) from Germany's R&D tax incentive program.
- Novartis terminated ieramilimab out-license agreement, patents to be assigned to Immutep.
- Granted seven new patents during the quarter.
Price Impact
More from IMMP
Immutep Q1 FY27: Efti focus shifts, IMP761 gains priority, cash $48.5M
Immutep Q4 FY26 Cash A$68.87M; TACTI-004 Futility Analysis Ongoing
Immutep Reports Positive INSIGHT-003 NSCLC Data; TACTI-004 Analysis Ongoing